Obagi Medical Taps 9,000 Clinics for ALOHA Real-World Data on New Injectable
Obagi Medical has selected Aesthetic Record’s EMR platform—used by over 9,000 aesthetic clinics—to generate real-world evidence for its new injectable, Obagi saypha MagIQ, via the ALOHA Program. The initiative will capture standardized safety and efficacy data across multiple practices ahead of industry conference presentations.
1. Partnership Overview
Obagi Medical, part of Waldencast plc, has partnered with Aesthetic Record to leverage its EMR and practice management platform for the ALOHA Program. Aesthetic Record’s technology was chosen for its seamless charting, analytics and integration capabilities supporting over 9,000 aesthetic clinics nationwide.
2. ALOHA Real-World Program
The ALOHA Program will deploy Obagi saypha MagIQ™, a novel hyaluronic acid injectable, across multiple high-volume practices to collect real-world safety, efficacy and patient satisfaction data. Standardized data capture and performance tracking will translate FDA trial results into everyday clinical settings.
3. Future Presentations and Impact
Initial findings from the ALOHA Program will be showcased at the upcoming Aesthetic Next conference, with subsequent presentations at key industry events. This real-world evidence is designed to strengthen provider confidence, accelerate launch success and inform broader adoption of Obagi’s injectable aesthetics solutions.